New DNA Test Predicts Health and Mortality Better Than Traditional Biomarkers
Scientists developed PhysAge, a DNA methylation test that outperforms standard blood tests in predicting aging and death risk.
Summary
Researchers created PhysAge, a revolutionary DNA methylation test that measures biological aging across eight key health systems. Unlike traditional blood tests, PhysAge analyzes how genes are switched on or off to predict health outcomes. Testing on over 5,000 adults showed PhysAge matched the accuracy of leading aging clocks in predicting mortality risk, while also forecasting grip strength, walking speed, cognitive function, and frailty. The test translates complex molecular data from inflammation, lung function, blood pressure, cholesterol, blood sugar, body composition, kidney function, and hormone levels into a single aging score. This breakthrough offers a more comprehensive view of biological age than chronological age alone, potentially revolutionizing how we monitor health and longevity.
Detailed Summary
Traditional health assessments rely on individual biomarkers like cholesterol or blood pressure, but a groundbreaking study reveals that DNA methylation patterns provide superior insights into biological aging and mortality risk.
Researchers developed PhysAge, a novel aging clock that analyzes DNA methylation patterns representing eight physiological systems: inflammation (CRP), lung function (peak flow), cardiovascular health (pulse pressure), cholesterol metabolism (HDL), blood sugar control (HbA1c), body composition (waist-to-height ratio), kidney function (cystatin C), and hormone levels (DHEAS). The team studied over 5,000 adults across three major cohorts in the US and Ireland.
PhysAge demonstrated remarkable predictive power, matching GrimAge2's accuracy in forecasting mortality while excelling at predicting physical function, cognitive performance, and frailty. Surprisingly, the DNA-based surrogates often outperformed actual measured biomarker values in health predictions. The test performed comparably to established second-generation epigenetic clocks despite not being specifically trained on mortality data.
This advancement could transform personalized medicine by providing a single, comprehensive biological age score rather than interpreting multiple separate test results. PhysAge offers clinicians and individuals a powerful tool for monitoring health trajectories and intervention effectiveness across multiple body systems simultaneously.
While promising, the study focused on older adults and requires validation across diverse populations and age groups. The complexity of DNA methylation analysis currently limits widespread clinical implementation, though costs continue decreasing as technology advances.
Key Findings
- PhysAge DNA test matched leading mortality predictors without being trained on death data
- DNA methylation surrogates often predicted health better than actual measured biomarkers
- Single test captures aging across eight major physiological systems simultaneously
- Accurately predicted grip strength, walking speed, cognitive function, and frailty risk
- Validated across over 5,000 adults in multiple international cohorts
Methodology
Researchers analyzed DNA methylation data from 5,495 adults across three cohorts: US Health and Retirement Study (3,177 participants), Irish TILDA study (488), and Northern Ireland NICOLA study (1,830). The study used split-sample validation with training and test groups, comparing PhysAge against established epigenetic clocks.
Study Limitations
The study focused primarily on older adults, limiting generalizability to younger populations. DNA methylation testing remains more complex and expensive than standard blood tests, potentially limiting immediate clinical adoption. Long-term validation studies across diverse populations are still needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.